Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund’s top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focusing on developing and commercializing therapies for treating cystic fibrosis (CF). The one-month return of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was -11.28%, and its shares gained 1.61% of their value over the last 52 weeks. On May 8, 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock closed at $429.60 per share with a market capitalization of $110.32 billion. Baron Health Care Fund stated the following regarding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its Q1 2025 investor letter: "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a leading biotechnology company with a cystic fibrosis franchise and a pipeline of drugs for other conditions. Shares increased on a recovery in investor sentiment after disappointing data from Journvax in lumbar spinal radiculopathy in December. We remain bullish on Vertex’s cystic fibrosis business and its evolving pipeline, including Journvax, a non-opioid NaV inhibitor currently in launch for the treatment of acute pain. Although Vertex needs to finalize utilization management criteria with payers, we see a high level of unmet need and large potential market. Vertex’s broader pipeline for pain treatment includes several additional non-opioid NaV inhibitor assets. We are also encouraged by its pipeline in kidney disease, including inaxaplin for APOL1-mediated kidney disease and povetacicept for IgA nephropathy."Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires? A pharmacist delivering a specific medication to a patient in a specialty pharmacy. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 68 hedge fund portfolios held Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at the end of the fourth quarter which was 55 in the previous quarter. In the first quarter Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported $2.77 billion in revenues, up 3% from Q1 2024. While we acknowledge the potential of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. Story Continues In another article, we covered Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and shared the list of stocks on Jim Cramer’s radar. In the first quarter of 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranked as GreensKeeper Asset Management's second-largest holding. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...